Kosan restructures to focus resources on lead clinical programmes
US-based biotech company Kosan Biosciences is to reduce its workforce by approximately 37% to focus resources on supporting advancement of its lead clinical programmes, tanespimycin in multiple myeloma and in metastatic breast cancer, and epothilone KOS-1584 in non-small lung cancer.
US-based biotech company Kosan Biosciences is to reduce its workforce by approximately 37% to focus resources on supporting advancement of its lead clinical programmes, tanespimycin in multiple myeloma and in metastatic breast cancer, and epothilone KOS-1584 in non-small lung cancer.
The restructuring will primarily affect the company's research and administrative functions. As a result of the restructuring, most research programmes will be placed on hold. The company may seek to partner these assets with companies looking for early-stage programmes.
"Restructuring our workforce to focus resources on development of our lead clinical programmes completes the strategic reprioritisation of Kosan's development portfolio," said ceo Helen S. Kim. "This represents an important step in Kosan's evolution to a product-oriented company.
"We believe that this restructuring will strengthen our ability to effectively manage our resources, execute our development goals and advance our high-value, near-term commercial opportunities."